放疗联合奥沙利铂与卡培他滨治疗局部晚期直肠癌临床疗效探讨.docVIP

放疗联合奥沙利铂与卡培他滨治疗局部晚期直肠癌临床疗效探讨 　　[摘要] 目的 探析放疗联合奥沙利铂与卡培他滨治疗局部晚期直肠癌的临床疗效。 方法 随机选取2012年1月―2015年8月该院收治的60例局部晚期直肠癌患者，将其分为研究组和对照组，各为30例，研究组采取放疗联合奥沙利铂与卡培他滨治疗，对照组仅采取奥沙利铂与卡培他滨治疗，对比分析治疗效果及不良反应情况。结果 研究组生存率为50.0%，复发率为33.3%，远处转移率为26.7%较对照组比较差异具有统计学意义P0.05，主要为白细胞减少和恶心呕吐等。 结论 局部晚期直肠癌患者术后进行放疗联合奥沙利铂与卡培他滨治疗效果显著，没有增加不良反应，可选为标准治疗方案。 　　[关键词] 放疗；奥沙利铂；卡培他滨；直肠癌 　　[中图分类号] R735.37 [文献标识码] A [文章编号] 1674-0742（2015）12（a）-0130-02 　　[Abstract] Objective To explore the clinical efficacy of radiotherapy combined with oxaliplatin and capecitabine in the treatment of locally advanced rectal cancer. Methods 60 patients with locally advanced rectal cancer admitted to our hospital from January 2012 and August 2015 were included and divided into study group and control group with 30 in each. The study group was treated with radiotherapy combined with oxaliplatin and capecitabine， while the control group was treated only with oxaliplatin and capecitabine. The curative effect and adverse reaction was comparatively analyzed. Results The survival rate was 50.0%， the recurrence rate was 33.3%， and the distant metastasis rate was 26.7% in the study group， and compared with those in the control group， there were statistically significant differences between them， P0.05； no statistically significant difference can be found in adverse reaction between the two groups， which mainly included leukocytopenia， nausea and vomiting， etc. Conclusion The clinical efficacy of radiotherapy combined with oxaliplatin and capecitabine in the treatment of locally advanced rectal cancer is evident， which can not increase adverse reactions. Therefore it can be considered as the standard treatment. 　　[Key words] Radiotherapy； Oxaliplatin； Capecitabine； Colorectal cancer 　　直肠癌属于较为常见的恶性肿瘤之一，直肠癌早期症状比较隐匿，一般情况下患者被确诊为直肠癌，已经处于中晚期的状态，增加了对周围脏器的损坏，同时也增加了发生远处转移的几率，手术切除是目前主要的治疗方案，对于术后辅助治疗主要是放化疗[1-2]。为探析放疗联合奥沙利铂与卡培他滨治疗局部晚期直肠癌的临床疗效，该研究将2012年1月―2015年8月该院收治的60例局部晚期直肠癌患者为本次研究的对象，现报道如下。 　　1 资料与方法 　　1.1 一般资料 　　随机选取2012年1月―2015年8月该院收治的60例局部晚期直